Abstract
Inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, and inflammatory bowel disease-unclassified, is a complex intestinal disease influenced by microbial factors, genetic and environmental. IBD has become a global disease with an increasing prevalence, endangering human health worldwide. Through its interactions with host immunity, bacterial metabolites, and genetic components, the intestinal microbiome plays a crucial role in initiating and advancing IBD. Treatment for IBD includes not only corticosteroids, aminosalicylates, antibiotics, TNF-α, α4β7 integrins, IL-12/23 antibodies, and small molecule antibodies, but also complementary and alternative medical therapies such as probiotics and prebiotics. This review primarily explores the relationship between dysbiosis of the microbiota and IBD, including the immune system, metabolites, and genetics related to microorganisms, to provide a deeper and more systematic understanding of the mechanisms linking microbial imbalance to IBD.